Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Exchange Rate Effect (2022 - 2025)

Zevra Therapeutics' Exchange Rate Effect history spans 4 years, with the latest figure at -$322000.0 for Q4 2025.

  • For Q4 2025, Exchange Rate Effect fell 147.99% year-over-year to -$322000.0; the TTM value through Dec 2025 reached $28000.0, down 93.83%, while the annual FY2025 figure was $28000.0, 93.83% down from the prior year.
  • Exchange Rate Effect reached -$322000.0 in Q4 2025 per ZVRA's latest filing, down from $64000.0 in the prior quarter.
  • In the past five years, Exchange Rate Effect ranged from a high of $671000.0 in Q4 2024 to a low of -$491000.0 in Q3 2024.
  • Average Exchange Rate Effect over 4 years is $52142.9, with a median of $39500.0 recorded in 2022.
  • Peak YoY movement for Exchange Rate Effect: plummeted 780.0% in 2023, then surged 219.03% in 2024.
  • A 4-year view of Exchange Rate Effect shows it stood at $189000.0 in 2022, then soared by 84.66% to $349000.0 in 2023, then soared by 92.26% to $671000.0 in 2024, then crashed by 147.99% to -$322000.0 in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Exchange Rate Effect are -$322000.0 (Q4 2025), $64000.0 (Q3 2025), and $658000.0 (Q2 2025).